Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0001143,
umls-concept:C0007589,
umls-concept:C0010453,
umls-concept:C0012426,
umls-concept:C0040845,
umls-concept:C0086418,
umls-concept:C0205174,
umls-concept:C0205178,
umls-concept:C0205195,
umls-concept:C0205225,
umls-concept:C0205263,
umls-concept:C0368761,
umls-concept:C0439677,
umls-concept:C1511938
|
pubmed:issue |
3
|
pubmed:dateCreated |
1989-9-11
|
pubmed:abstractText |
Differentiation induction therapy provides unalternative for treatment of acute myeloid leukaemia (AML) patients who are either unsuitable for or unresponsive to conventional cytotoxic chemotherapy. The effect of a triple combination of retinoic acid(RA)+aclacinomycin A (ACM)+dimethylformamide (DMF) on differentiation of blasts from 24 AML patients was studied. Non-adherent mononuclear cells were seeded at a concentration of 5 x 10(5) cells/ml in 24-well tissue culture plates containing RPM11640 culture medium with 20% fetal calf serum and 10% 5637-conditioned medium and incubated with 10(-6) M retinoic acid, 80nM aclacinomycin A and/or 100mM dimethylformamide alone and in combinations with each other for six days at 37 degrees C in a humidified incubator under 5% CO2. Morphological, cytochemical and functional differentiation into mature cells were induced in blasts from 22 out of the 24 AML patients after exposure to the triple combination of 10(-6)M RA+80nM ACM+100mM DMF for 6 days in primary culture. These highly effective results justify a clinical trial of this triple combination for AML patients who are either unsuitable for or unresponsive to conventional cytotoxic chemotherapy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0250-7005
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
647-51
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2764511-Aclarubicin,
pubmed-meshheading:2764511-Cell Differentiation,
pubmed-meshheading:2764511-Dimethylformamide,
pubmed-meshheading:2764511-Drug Combinations,
pubmed-meshheading:2764511-Humans,
pubmed-meshheading:2764511-Leukemia, Myeloid, Acute,
pubmed-meshheading:2764511-Neoplastic Stem Cells,
pubmed-meshheading:2764511-Tretinoin,
pubmed-meshheading:2764511-Tumor Cells, Cultured
|
pubmed:articleTitle |
Triple combination of retinoic acid+aclacinomycin A+ dimethylformamide induces differentiation of human acute myeloid leukaemic blasts in primary culture.
|
pubmed:affiliation |
Department of Haematological Medicine, University of Cambridge Clinical School, England, U.K.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|